

# Ralf Gutzmer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399412/publications.pdf>

Version: 2024-02-01

204  
papers

23,582  
citations

28736

57  
h-index

9605

147  
g-index

220  
all docs

220  
docs citations

220  
times ranked

26478  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
2	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. <i>European Journal of Cancer</i> , 2022, 161, 99-107.	1.3	10
3	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. <i>Cancers</i> , 2022, 14, 518.	1.7	6
4	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	0.8	43
5	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	1.7	4
6	Prognostic and predictive value of $\checkmark$ -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
7	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. <i>European Journal of Cancer</i> , 2022, 166, 60-72.	1.3	7
8	MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. <i>European Journal of Cancer</i> , 2022, 167, 32-41.	1.3	9
9	Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF <sup>V600</sup> -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING <sup>MELANOMA</sup> .. <i>Journal of Clinical Oncology</i> , 2022, 40, 9526-9526.	0.8	0
10	Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAF <sup>V600</sup> mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9547-9547.	0.8	5
11	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF <sup>V600</sup> -positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	0.8	6
12	Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. , 2022, 10, e004509.		8
13	The H <sub>4</sub> R is highly expressed on eosinophils from AD patients and IL-4 upregulates expression and function via the JAK/STAT pathway. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1261-1264.	2.7	9
14	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1763-1771.	1.2	2
15	SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry. <i>European Journal of Cancer</i> , 2021, 144, 382-385.	1.3	18
16	Histamine downregulates the FCER1 chain expression in human IL-4-activated M2 macrophages. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1250-1254.	2.7	1
17	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	0.5	1
18	Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. , 2021, 9, e001621.		32

#	ARTICLE	IF	CITATIONS
19	Reply to E. HindiÃ©. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
20	PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT. JDDG - Journal of the German Society of Dermatology, 2021, 19, 852-862.	0.4	5
21	Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF<sup>V600</sup>-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING<sup>MELANOMA</sup>.. Journal of Clinical Oncology, 2021, 39, 9555-9555.	0.8	0
22	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
23	KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology, 2021, 39, 9546-9546.	0.8	0
24	Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.. Journal of Clinical Oncology, 2021, 39, 9568-9568.	0.8	1
25	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€œ A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	1.3	10
26	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	1.3	2
27	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15
28	Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. Cancers, 2021, 13, 2319.	1.7	15
29	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 643-654.	5.1	224
30	Response to letter entitled: â€œRe: Hematological immune related adverse events after treatment with immune checkpoint inhibitorsâ€™. European Journal of Cancer, 2021, 153, 272-273.	1.3	1
31	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncology, The, 2021, 22, 848-857.	5.1	150
32	Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. European Journal of Cancer, 2021, 152, 139-154.	1.3	13
33	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 2021, 13, 3359.	1.7	18
34	Expression of histamine receptors H2R and H4R are predominantly regulated via the IL4/IL13 receptor type II on human M2 macrophages. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2886-2890.	2.7	6
35	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	1.3	7
36	Sirolimus diminishes the expression of GRO-1 (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells. Journal of Dermatological Science, 2021, 104, 30-38.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 741993.	1.3	9
38	Update â€œ Systemtherapie beim Basalzellkarzinom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1399-1400.	0.4	0
39	Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1839-1849.	1.4	9
40	Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 733961.	2.2	5
41	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition â€œ A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
42	Aggressive gamma/delta T-cell lymphoma: successful therapy with encapsulated doxorubicin. <i>European Journal of Cancer</i> , 2021, 156, S57.	1.3	0
43	Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11648.	1.8	11
44	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 159, 113-124.	1.3	13
45	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. <i>BMC Cancer</i> , 2021, 21, 1244.	1.1	7
46	The role of the histamine H <sub>4</sub> receptor in atopic dermatitis and psoriasis. <i>British Journal of Pharmacology</i> , 2020, 177, 490-502.	2.7	51
47	Stimulation of histamine H <sub>4</sub> receptors increases the production of IL-9 in Th9 polarized cells. <i>British Journal of Pharmacology</i> , 2020, 177, 614-622.	2.7	6
48	Histamine up-regulates oncostatin M expression in human M1 macrophages. <i>British Journal of Pharmacology</i> , 2020, 177, 600-613.	2.7	18
49	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130
50	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
51	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	1.3	47
52	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
53	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	1.3	44
54	Melanoma brain metastases â€œ Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , 2020, 89, 102083.	3.4	52

#	ARTICLE	IF	CITATIONS
55	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. <i>Oncolimmunology</i> , 2020, 9, 1824645.	2.1	31
56	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
57	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
58	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
59	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
60	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
61	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
62	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
63	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1835-1844.	6.3	423
64	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 275-294.	0.4	57
65	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 400-413.	0.4	39
66	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
67	Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. <i>Frontiers in Immunology</i> , 2020, 11, 588582.	2.2	24
68	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10012-10012.	0.8	14
69	Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10023-10023.	0.8	7
70	Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAF <sup>V600+</sup> melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10073-10073.	0.8	2
71	Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma. <i>Oncotarget</i> , 2020, 11, 3473-3483.	0.8	2
72	Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. <i>European Journal of Cancer</i> , 2019, 119, 18-29.	1.3	44

#	ARTICLE	IF	CITATIONS
73	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
74	Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. <i>Targeted Oncology</i> , 2019, 14, 253-267.	1.7	45
75	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27
76	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91.	1.3	15
77	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy – Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019, 8, 1777.	1.0	87
78	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
79	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
80	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	2.0	140
81	Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1187-1194.	2.0	40
82	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
83	Hedgehog signaling inhibitors in solid and hematological cancers. <i>Cancer Treatment Reviews</i> , 2019, 76, 41-50.	3.4	90
84	Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation. <i>Journal of Skin Cancer</i> , 2019, 2019, 1-11.	0.5	16
85	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2019, 110, 11-20.	1.3	44
86	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	2.0	35
87	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	15.2	541
88	Acute progressive neuropathy – myositis – myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23
89	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	1.3	171
90	Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry. <i>Journal of Clinical Oncology</i> , 2019, 37, 9505-9505.	0.8	12

#	ARTICLE	IF	CITATIONS
91	Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.. Journal of Clinical Oncology, 2019, 37, 9526-9526.	0.8	27
92	Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. Deutsches A&#x0308;rztblatt International, 2019, 116, 616-626.	0.6	15
93	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. European Journal of Cancer, 2018, 93, 150-153.	1.3	43
94	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunology, Immunotherapy, 2018, 67, 825-834.	2.0	91
95	The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1Î² from fully differentiated M1 macrophages. Inflammation Research, 2018, 67, 503-513.	1.6	19
96	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801.	13.9	1,441
97	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patternsâ€”Results of a non-interventional study of the DeCOG. European Journal of Cancer, 2018, 96, 34-43.	1.3	97
98	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	2.9	34
99	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine, 2018, 7, 95-104.	1.3	16
100	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 603-615.	5.1	751
101	Histamine H2 receptor stimulation upregulates T H 2 chemokine CCL17 production in human M2a macrophages. Journal of Allergy and Clinical Immunology, 2018, 141, 782-785.e5.	1.5	8
102	PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. European Journal of Cancer, 2018, 88, 67-76.	1.3	15
103	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIVÂor hepatitis B/C infection. European Journal of Cancer, 2018, 104, 137-144.	1.3	97
104	The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes. Journal of Dermatological Science, 2018, 92, 172-180.	1.0	8
105	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1315-1327.	5.1	469
106	Melanoma. Lancet, The, 2018, 392, 971-984.	6.3	1,016
107	Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS ONE, 2018, 13, e0197780.	1.1	9
108	The Anaphylatoxin C3a Receptor Expression on Human M2 Macrophages Is Down-Regulated by Stimulating the Histamine H4 Receptor and the IL-4 Receptor. Journal of Innate Immunity, 2018, 10, 349-362.	1.8	17

#	ARTICLE	IF	CITATIONS
109	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018, 27, e12901.	0.7	19
110	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	5.1	131
111	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	0.8	23
112	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9527-9527.	0.8	25
113	BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9542-9542.	0.8	1
114	Adverse events of special interest in the phase 3 COLUMBUS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9567-9567.	0.8	3
115	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21588-e21588.	0.8	15
116	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. <i>Oncotarget</i> , 2018, 9, 26217-26225.	0.8	6
117	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. <i>European Journal of Cancer</i> , 2017, 75, 24-32.	1.3	162
118	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55.	1.3	145
119	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	5.1	399
120	Die Entwicklung der Therapie des Melanoms geht weiter â€“ Berichte von den Jahrestagungen ESMO und SMR im Oktober/November 2016. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 350-352.	0.4	1
121	Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis. <i>Journal of Dermatological Science</i> , 2017, 87, 130-137.	1.0	17
122	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
123	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. <i>European Journal of Cancer</i> , 2017, 81, 36-44.	1.3	76
124	Acquired IFN $\gamma$ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	5.8	195
125	Ist eine komplette Lymphknotendissektion beim malignen Melanom mit positivem Sentinel notwendig?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1175-1176.	0.4	2
126	Clinics, prognosis and new therapeutic options in patients with mucosal melanoma. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.4	50



#	ARTICLE	IF	CITATIONS
127	Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?. <i>Cancer Medicine</i> , 2017, 6, 1581-1586.	1.3	26
128	Phase 1b/2 trial of ribociclib+binimetinib in metastatic <i>NRAS</i> -mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9519-9519.	0.8	32
129	Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600E mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9526-9526.	0.8	5
130	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , 2017, 8, 76029-76043.	0.8	7
131	Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes. <i>Experimental Dermatology</i> , 2016, 25, 775-782.	1.4	12
132	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
133	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	1.3	490
134	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
135	Genetic variations within the promotor region of the human histamine H4 receptor gene in psoriasis patients. <i>Pharmacological Research</i> , 2016, 114, 121-127.	3.1	5
136	Stimulation of the histamine 4 receptor upregulates thymic stromal lymphopoietin (TSLP) in human and murine keratinocytes. <i>Pharmacological Research</i> , 2016, 113, 209-215.	3.1	22
137	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 113-125.e5.	0.6	133
138	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	3.4	354
139	BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma. <i>JAMA Dermatology</i> , 2016, 152, 228.	2.0	7
140	Aktuelle Diagnostik und Behandlung des Basalzellkarzinoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 863-877.	0.4	1
141	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 716-728.	5.1	325
142	The Histamine H4 Receptor Regulates Chemokine Production in Human Natural Killer Cells. <i>International Archives of Allergy and Immunology</i> , 2015, 166, 225-230.	0.9	12
143	Current diagnosis and treatment of basal cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 863-875.	0.4	45
144	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	1.3	269

#	ARTICLE	IF	CITATIONS
145	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 375-384.	5.1	2,353
146	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 4077-4084.	0.8	29
147	International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. <i>Pharmacological Reviews</i> , 2015, 67, 601-655.	7.1	457
148	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
149	Allele frequencies of BRAF V600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 37895-37905.	0.8	26
150	The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment – Differences between the patient's and the physician's perspective.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20099-e20099.	0.8	0
151	Basal Cell Carcinoma. <i>Deutsches Ärzteblatt International</i> , 2014, 111, 389-95.	0.6	64
152	Partielle Remission Feines Hirn infiltrierenden Basalzellkarzinoms durch Vismodegib. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 906-907.	0.4	3
153	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678.	1.6	81
154	Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas. <i>Melanoma Research</i> , 2014, 24, 158-164.	0.6	7
155	Histamine Downregulates the Th1-Associated Chemokine IP-10 in Monocytes and Myeloid Dendritic Cells. <i>International Archives of Allergy and Immunology</i> , 2014, 163, 11-19.	0.9	19
156	Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR inhibitors in organ transplant recipients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 480-488.	0.4	26
157	Rückgang nicht-melanozytärer Hauttumoren nach Umstellung der Immunsuppression auf mTOR-Inhibitoren bei organtransplantierten Patienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 480-490.	0.4	10
158	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9041-9041.	0.8	2
159	The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9113-TPS9113.	0.8	0
160	Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4-receptor. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1358-1367.	1.5	81
161	Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial). <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 846-853.	0.4	6
162	Malignes Melanom S3-Leitlinie – Diagnostik, Therapie und Nachsorge des Melanoms – <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-126.	0.4	9

#	ARTICLE	IF	CITATIONS
163	Malignant Melanoma S3-Guideline "Diagnosis, Therapy and Follow-up of Melanoma"; JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.4	122
164	Kutane Nebenwirkungen der Kombinationstherapie mit Sorafenib und pegyliertem Interferon alfa-2b bei metastasiertem Melanom (ADO SoraPeg-Studie). JDDG - Journal of the German Society of Dermatology, 2013, 11, 846-854.	0.4	5
165	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9013-9013.	0.8	68
166	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 2013, 8, e53745.	1.1	414
167	Histamine down-regulates IL-27 production in antigen-presenting cells. Journal of Leukocyte Biology, 2012, 92, 21-29.	1.5	29
168	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	6.3	2,691
169	Human Memory Th17 Cells Express a Functional Histamine H4 Receptor. American Journal of Pathology, 2012, 180, 177-185.	1.9	65
170	Cutaneous Side Effects of New Antitumor Drugs. Deutsches A&#x0308;rztblatt International, 2012, 109, 133-40.	0.6	40
171	Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. JDDG - Journal of the German Society of Dermatology, 2012, 10, 559-562.	0.4	6
172	Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).. Journal of Clinical Oncology, 2012, 30, 8505-8505.	0.8	4
173	Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF <sup>V600E</sup>-mutated melanoma.. Journal of Clinical Oncology, 2012, 30, LBA8500-LBA8500.	0.8	12
174	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. Journal of Clinical Oncology, 2012, 30, e19031-e19031.	0.8	0
175	The Histamine H4 Receptor Is Highly Expressed on Plasmacytoid Dendritic Cells in Psoriasis and Histamine Regulates Their Cytokine Production and Migration. Journal of Investigative Dermatology, 2011, 131, 1668-1676.	0.3	58
176	Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus. Frontiers in Bioscience - Scholar, 2011, S3, 985.	0.8	40
177	Histamine H4 receptor activation on human slan-dendritic cells down-regulates their pro-inflammatory capacity. Immunology, 2011, 132, 49-56.	2.0	38
178	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. JDDG - Journal of the German Society of Dermatology, 2011, 9, 195-202.	0.4	28
179	The Role of the Histamine H4 Receptor in Atopic Dermatitis. Current Allergy and Asthma Reports, 2011, 11, 21-28.	2.4	30
180	Reply to assessment of capsular melanoma cell deposits in sentinel lymph nodes. Cancer, 2011, 117, 2821-2821.	2.0	0

#	ARTICLE	IF	CITATIONS
181	Which Parameters to Choose for Prediction of Non-Sentinel Lymph Node Positivity in Melanoma?. Journal of Clinical Oncology, 2011, 29, e315-e315.	0.8	4
182	The hand-foot syndrome associated with medical tumor therapy – classification and management. JDDG - Journal of the German Society of Dermatology, 2010, 8, 652-661.	0.4	77
183	Das Hand-Fuß-Syndrom als Nebenwirkung der medikamentösen Tumorthherapie - Klassifikation und Management. JDDG - Journal of the German Society of Dermatology, 2010, 8, 652-662.	0.4	49
184	Histamine H <sub>4</sub> receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Experimental Dermatology, 2009, 18, 57-63.	1.4	125
185	Pharmacological characterization of the new histamine H <sub>4</sub> receptor agonist VU175603. British Journal of Pharmacology, 2009, 157, 34-43.	2.7	56
186	The histamine H4 receptor is functionally expressed on TH2 cells. Journal of Allergy and Clinical Immunology, 2009, 123, 619-625.	1.5	199
187	Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas. JDDG - Journal of the German Society of Dermatology, 2008, 6, 198-203.	0.4	57
188	Histamine Upregulates Keratinocyte MMP-9 Production via the Histamine H1 Receptor. Journal of Investigative Dermatology, 2008, 128, 2783-2791.	0.3	50
189	Human Inflammatory Dendritic Epidermal Cells Express a Functional Histamine H4 Receptor. Journal of Investigative Dermatology, 2008, 128, 1696-1703.	0.3	96
190	Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. Journal of Allergy and Clinical Immunology, 2007, 120, 300-307.	1.5	115
191	Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. International Journal of Cancer, 2007, 121, 2562-2566.	2.3	36
192	Human Plasmacytoid Dendritic Cells Express Receptors for Anaphylatoxins C3a and C5a and Are Chemoattracted to C3a and C5a. Journal of Investigative Dermatology, 2006, 126, 2422-2429.	0.3	64
193	Critical involvement of IL-12 in IFN- $\gamma$ induction by calcineurin antagonists in activated human lymphocytes. Journal of Leukocyte Biology, 2006, 80, 75-86.	1.5	8
194	Induction of C3 and CCL2 by C3a in Keratinocytes: A Novel Autocrine Amplification Loop of Inflammatory Skin Reactions. Journal of Immunology, 2006, 177, 4444-4450.	0.4	39
195	Human Keratinocytes Respond to Interleukin-18: Implication for the Course of Chronic Inflammatory Skin Diseases. Journal of Investigative Dermatology, 2005, 124, 1225-1233.	0.3	94
196	Histamine H4 Receptor Stimulation Suppresses IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells. Journal of Immunology, 2005, 174, 5224-5232.	0.4	210
197	Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons. Immunology, 2004, 111, 435-443.	2.0	60
198	Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2. Immunology, 2003, 110, 458-465.	2.0	21

#	ARTICLE	IF	CITATIONS
199	Human Dendritic Cells Express the IL-18R and Are Chemoattracted to IL-18. <i>Journal of Immunology</i> , 2003, 171, 6363-6371.	0.4	83
200	Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 524-531.	1.5	83
201	Absence of HHV-8 DNA in hobnail hemangiomas. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 154-158.	0.7	14
202	Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. <i>Histopathology</i> , 2002, 41, 510-518.	1.6	29
203	Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. <i>British Journal of Dermatology</i> , 2002, 147, 160-165.	1.4	47
204	Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. <i>Human Genetics</i> , 2000, 107, 357-361.	1.8	48